Sage Therapeutics (NASDAQ: SAGE)
Sage Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sage Therapeutics Company Info
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.
News & Analysis
Why Sage Therapeutics Stock Sank Today
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
The pharmaceutical company's growth prospects have taken a big hit.
Why Shares of Sage Therapeutics Slumped This Week
The company got bad news from the FDA and saw increased losses.
Is Sage Therapeutics a Contrarian Buy?
A regulatory setback weighed heavily on the drugmaker's shares Monday.
Why Sage Therapeutics Stock Is Crashing Today
Sage's regulatory win wasn't enough to offset an even bigger regulatory loss.
Why Sage Therapeutics Stock Is Tumbling Today
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.
Why Shares of Sage Therapeutics Climbed 15.6% This Week
Investors can see the finish line for the company's second marketed therapy.
Why Sage Therapeutics Stock Is Crashing Today
The late-stage trial results for the company's major depressive disorder drug aren't impressing investors today.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.